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DOI 10.1016/j.ccr.2011.09.008SUMMARYChromosomal translocations involving the mixed lineage leukemia (MLL) gene lead to the development of
acute leukemias. Constitutive HOX gene activation by MLL fusion proteins is required for MLL-mediated
leukemogenesis; however, the underlying mechanisms remain elusive. Here, we show that chromobox
homolog 8 (CBX8), a Polycomb Group protein that interacts with MLL-AF9 and TIP60, is required for MLL-
AF9-induced transcriptional activation and leukemogenesis. Conversely, both CBX8 ablation and specific
disruption of the CBX8 interaction by point mutations in MLL-AF9 abrogate HOX gene upregulation and
abolish MLL-AF9 leukemic transformation. Surprisingly, Cbx8-deficient mice are viable and display no
apparent hematopoietic defects. Together, our findings demonstrate that CBX8 plays an essential role in
MLL-AF9 transcriptional regulation and leukemogenesis.INTRODUCTION
Mixed lineage leukemia (MLL), a human homolog of the
Drosophila trithorax group (TrxG) protein, is a histone H3 lysine
4-specific methyltransferase commonly associated with tran-
scriptional activation (Krivtsov and Armstrong, 2007; Nakamura
et al., 2002). MLL is essential for both embryonic development
and normal hematopoiesis, mainly through transcriptional regu-
lation of the homeobox (HOX) gene family and their cofactors
(Dou and Hess, 2008). Chromosome translocations at the MLL
locus that generate oncogenic MLL fusion proteins are one of
the major genetic lesions leading to acute leukemias. In total,
MLL translocations account for up to 80% of infant leukemias
and approximately 10% of adult acute leukemias with generally
poor prognosis (Aplan, 2006; Muntean et al., 2010). To date,Significance
MLL translocations that generate MLL-rearranged oncoprotein
aberrant target gene activation is known as the primary driver
nisms remain poorly understood. Here, we demonstrate that ch
scription repressor, is a crucial cofactor required forMLL-AF9-i
repressive complex 1, CBX8 facilitates the transcriptional activ
the recruitment of the histone acetyltransferase TIP60. Striking
tion, CBX8 appears dispensable for normal hematopoiesis. O
CBX8 and MLL-AF9 may be an effective therapeutic strategy
Canmore than 50 different translocation partners have been identi-
fied, of which the most common ones are the transcriptional
activators AF9, ENL, and AF4 (Krivtsov and Armstrong, 2007;
Monroe et al., 2011; Yokoyama et al., 2010).
It is well established that constitutive activation of HOX genes,
particularly HOXA9, is a key feature of MLL pathogenesis;
however, the molecular mechanisms governing the aberrant
HOX gene activation have not been completely deciphered (Sit-
wala et al., 2008; Yokoyama andCleary, 2008). Extensive studies
have been conducted to explore the functional significance of
both the retained MLL portion and the translocation partners of
MLL fusion proteins in transcriptional regulation. On the one
hand, the amino-terminal portion of MLL has been shown to be
required for the localization of MLL fusion proteins, due to its
DNA-binding ability (Ayton et al., 2004; Slany et al., 1998) ands are a common cause of human acute leukemias. Although
of MLL-rearranged leukemogenesis, the underlying mecha-
romobox homolog 8 (CBX8), a previously characterized tran-
nduced leukemogenesis. Contrary to its role in the polycomb
ation of MLL-AF9 target genes, possibly through regulating
ly, despite its essential role inMLL-AF9 leukemic transforma-
ur findings suggest that disrupting the interaction between
in MLL-rearranged leukemias.
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Moreover, we and others have shown that the polymerase-asso-
ciated factor complex (PAFc), an important component of the
basal transcriptional machinery, interacts with this region to
facilitate transcriptional activation and leukemic transformation
(Milne et al., 2010; Muntean et al., 2010; Tan et al., 2010). On
the other hand, the mechanisms by which the major fusion part-
ners contribute to MLL-rearranged leukemogenesis are begin-
ning to be defined (Monroe et al., 2011). It has been reported
that a complex of proteins termed ENL-associated proteins
(EAPs), or a closely related complex named AEP for AF4
family/ENL family/P-TEFb complex, interacts with the major
MLL fusion partners AF9, ENL, and AF4 (Lin et al., 2010;Muntean
et al., 2010; Yokoyama et al., 2010). The EAP complex includes
not only the common MLL fusion partners but also the histone
methyltransferase DOT1L and the P-TEFb complex (consisting
of CDK9 and cyclin T1), positively regulating transcription elon-
gation (Krivtsov et al., 2008; Mueller et al., 2007). Meanwhile,
other investigators have described an H3K79 methyltransferase
complex, DotCom, containing several frequent MLL fusion part-
ners, including AF9, ENL, and AF10, that plays a positive role in
leukemogenesis (Mohan et al., 2010b). The components of these
complexes partially overlap, suggesting the presence of sepa-
rate complexes that contribute to MLL-rearranged leukemogen-
esis (Mohan et al., 2010a; Mueller et al., 2007). Interestingly,
chromobox homolog 8 (CBX8), a Polycomb Group (PcG) protein
generally associated with transcription repression, is also
present in complexes recruited by MLL fusion proteins (Monroe
et al., 2011; Mueller et al., 2007). However, the significance of
this association has not been defined.
CBX8, also known as HPC3 (Human Polycomb 3), belongs to
the CBX protein family (including CBX2, 4, 6, 7, and 8) that is
homologs of the Drosophila Polycomb (Pc) protein (Kerppola,
2009). CBX8 was originally characterized as a transcriptional
repressor, interacting with RING1a/b and associating with BMI1
in the Polycomb repressive complex 1 (PRC1) (Ba´rdos et al.,
2000). A previous study has reported that as a PRC1 component,
CBX8 represses the INK4a/ARF expression in fibroblasts (Dietrich
et al., 2007). Further studies showed that several distinct PRC1
complexes colocalize and regulate INK4a/ARF expression, sug-
gesting that the INK4a/ARF locus is a general target for PRC1
complexes, rather than a CBX8-specific downstream target
(Maertens et al., 2009). Therefore, the exact role of CBX8 in
transcriptional regulation remains largely undefined. It has been
reported that certain CBX proteins, such as CBX4, can associate
with protein complexes other than PRC1, thereby playing a
PRC1-independent role in transcriptional regulation (Kerppola,
2009). However, it remains unknown whether CBX8 has a PRC1-
independent function and what its biological significance may be.
In the present study we investigated the role of CBX8 in MLL-
AF9-induced leukemogenesis and explored the underlying
mechanisms in relation to its involvement in PRC1.
RESULTS
CBX8 Specifically Interacts with MLL-AF9
at the C-Terminal Domain (CTD)
Previous studies have reported that the MLL fusion partner AF9
directly interacts with CBX8 through the evolutionarily conserved564 Cancer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier IncCTD (Figure 1A) (Garcı´a-Cue´llar et al., 2001; Hemenway et al.,
2001; Monroe et al., 2011). However, whether this interaction is
retained in the MLL-AF9 fusion protein has not been defined.
To address this question, we transiently coexpressed epitope-
tagged MLL-AF9 and CBX8 in human embryonic kidney 293
cells, using a FLAG-tagged ‘‘empty’’ vector as a negative
control. Specific interaction between CBX8 and MLL-AF9 was
detected by immunoprecipitation (IP) experiments. When using
AF9-conjugated agarose beads to pull down the full-length
fusion protein, we consistently observed that CBX8 coprecipi-
tated with MLL-AF9 (Figure 1B). To further characterize this
interaction, we performed IP experiments in the presence of
Benzonase. Using anti-FLAG antibody to pull down FLAG-
tagged MLL-AF9, we detected endogenous CBX8 coprecipitat-
ing with the fusion protein, indicating that CBX8 interacts with
MLL-AF9 in a DNA-independent manner (Figure 1C; see Fig-
ure S1A available online). Next, we characterized the critical
CBX8 interaction sites on MLL-AF9, by generating 15 point
mutants within the CTD through single amino acid substitution.
By coimmunoprecipitation (coIP) experiments, we identified
two point mutants (T542A and T554A) that specifically disrupt
the CBX8 interaction (Figures 1A and 1D). This observation
was further supported by reciprocal coIP experiments, using
anti-FLAG or anti-Myc antibodies to pull down CBX8 or
CxxC-AF9, respectively (Figure 1E; Figure S1B), in which case
CxxC-AF9, a previously characterized MLL-AF9 fragment, was
used as a surrogate for the full-length fusion protein (Muntean
et al., 2010).
Apart from CBX8, AF9 also associates either directly or indi-
rectly with DOT1L, the P-TEFb complex (CDK9 and CYCLINT1)
and AF5q31 (Monroe et al., 2011). Therefore, we asked whether
the CBX8 interaction is required for interaction with any of these
cofactors. To this end, we transiently transfected Myc-tagged
CxxC-AF9 (WT or the mutants) in 293 cells and found that the
P-TEFb complex (CDK9 and CYCLINT1) and AF5q31 coprecipi-
tated with both the WT CxxC-AF9 fragment and the mutants
(Figure 1F). Moreover, the interaction between DOT1L and
CxxC-AF9 was also retained in the T542A and T554A mutants,
as shown by reciprocal IP experiments using anti-FLAG or
anti-HA antibodies to pull down CBX8 or DOT1L, respectively
(Figure 1G; Figure S1C). This observation was further confirmed
by IP experiments in the context of full-length MLL-AF9 (Fig-
ure S1D). Together, our results showed that CBX8 specifically
interacts with MLL-AF9 at the CTD, and that disrupting the
CBX8 interaction does not affect the interaction with either
P-TEFb or DOT1L, both of which are required for MLL-AF9-
induced leukemogenesis.
CBX8 Is Essential for Both Initiation and Maintenance
of MLL-AF9 Leukemic Transformation
To assess the importance of the CBX8 interaction in MLL-AF9-
induced transformation, we first used bone marrow transforma-
tion (BMT) assays to examine the transformation ability of the
MLL-AF9 mutants (T542A and T554A), which lack the CBX8
interaction. Briefly, Lin- hematopoietic cells derived from primary
murine bone marrow (BM) were retrovirally transduced with
either WT MLL-AF9 or the mutants, followed by three consecu-
tive rounds of plating (Figure 2A). Despite the comparable
expression of the fusion transcripts, as confirmed by real-time.
Figure 1. CBX8 Specifically Interacts with MLL-AF9 at the CTD
(A) Schematic of full-length MLL-AF9. The amino acid sequence of the evolutionarily conserved CTD of AF9 is aligned with Drosophila, Rattus norvegicus,
and Mus musculus AF9 homologs. Arrows indicate the evolutionarily conserved threonine residues converted to alanine used below.
(B) coIP of FLAG-tagged CBX8 with fMLL-AF9 (f-MA9).
(C) coIP of endogenous CBX8 with f-MA9, after Benzonase treatment.
(D) coIP of endogenous CBX8 with WT FLAG-MA9, but not with the mutants (T542A and T554A).
(E) coIP of FLAG-CBX8 with WT Myc-CxxC-AF9, but not the mutants.
(F) coIP of endogenous CDK9, CYCLIN T1, and AF5q31 with both WT Myc-CxxC-AF9 and the mutants.
(G) coIP of both WT Myc-CxxC-AF9 and the mutants with HA-DOT1L. All of the coIP experiments included an epitope-tagged empty vector (FLAG-V or Myc-V)
as a control and were performed in 293 cells. A fraction (3%) of cell lysate was used for input control.
See also Figure S1.
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MLL Requires CBX8 for Leukemogenesisquantitative polymerase chain reaction (RT-qPCR), the T542A
and T554A mutations completely abolished myeloid transforma-
tion very early on, whereas the WT control potently transformed
primary hematopoietic cells, forming a large number of coloniesCan(Figures 2B and 2C). The tertiary colonies formed by WT MLL-
AF9-transduced cells displayed a dense, compact morphology,
indicative of immortalization. Wright-Giemsa staining shows
that these colonies are composed of myeloblasts (Figure 2D).cer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Inc. 565
Figure 2. CBX8/MLL-AF9 Interaction Is
Essential for MLL-AF9 Leukemic Transfor-
mation
(A) Experimental scheme of the BMT assays
evaluating the leukemic transformation ability of
WT MLL-AF9 and MLL-AF9 mutants (T542A and
T554A).
(B) RT-qPCR analysis of the expression levels of
WT MLL-AF9 and the mutants in Lin- BM after
retroviral transduction.
(C) Colony-forming units (CFU) per 20,000 plated
cells in each round of plating in methylcellulose.
Error bars represent ± standard deviation (SD)
from three independent experiments.
(D) Morphology of representative colonies from
primary BM cells transduced with indicated
constructs. The first row shows the representative
colony morphology in methylcellulose. Scale bars,
500 mm. The second row shows the p-iodoni-
trotetrazolium violet (INT)-stained colonies after
two rounds of plating. Dense red colonies are
visible fromWTMLL-AF9. The third row shows the
Wright-Giemsa-stained cells isolated after two
rounds of plating. Scale bars, 50 mm.
See also Figure S2.
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MLL Requires CBX8 for LeukemogenesisIn contrast, the MLL-AF9 mutant-transduced cells failed to form
colonies in the second round of selection, and they were
composedprimarily ofmonocytes andmacrophages (Figure 2D).
To further confirm that Cbx8 is required for MLL-AF9-induced
transformation, we transduced the MLL-AF9-transformed BM
cells with either the control shRNA or a shRNA directed against
Cbx8 after the third round plating, followed by puromycin selec-
tion (Figure S2A). Cbx8 expression, as measured by RT-qPCR,
was effectively downregulated (Figure S2B), whereas the
MLL-AF9 expression level was not significantly affected (p >
0.05; Figure S2C). As expected, knockdown of Cbx8 significantly
reduced the colony formation ability of MLL-AF9-transduced
cells, compared to the control (p < 0.01; Figures S2D and
S2E). Together, these results suggest that the CBX8/MLL-AF9
interaction is required for MLL-AF9-mediated immortalization.
We then used a conditional Cbx8 knockout mouse model
(generated by H.K.) to further assess the role of Cbx8 in initiation
and maintenance of transformation by MLL-fusion proteins
in vitro and in vivo (Figure 3A). Cbx8f/f mice were bred with
Rosa26-Cre-ERT2 mice to generate Cbx8 conditional knockout
mice. Treatment with 4-hydroxyltamoxifen (4-OHT) induced effi-
cient Cbx8 excision in primary BM cells from Cbx8f/f; Cre+ mice
(Figure 3B). To assess the role of Cbx8 in initiation and mainte-
nance of MLL-AF9 leukemic transformation, we induced Cbx8
excision by 4-OHT treatment, simultaneously with MLL-AF9
transduction or after selecting MLL-AF9-transformed cells by
three consecutive rounds of plating, respectively, with BM
from Cbx8f/f; Cre mice serving as a control (Figure 3C). The
expression level of MLL-AF9 was not significantly altered by
4-OHT treatment in either of these experimental settings (Figures
S3B and S3C). Strikingly, loss of Cbx8 completely abolished
colony formation by MLL-AF9-transduced cells under both
conditions (Figures 3D–3F; Figure S3A). In contrast to the colo-
nies formed by Cbx8f/f; Cre+ cells with the control treatment566 Cancer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Incand the Cbx8f/f; Cre control cells with or without 4-OHT treat-
ment, which showed dense morphology and were composed
predominantly of myeloblasts (Figure 3G; data not shown),
Cbx8-depleted cells failed to form colonies and were composed
of monocytes and macrophages (Figure 3G). Together, our
results strongly indicate that Cbx8 is essential for both initiation
and maintenance of MLL-AF9 leukemic transformation.
Given our findings with the BMT assay, an in vitro surrogate for
assessing myeloid transformation ability (Cheung et al., 2007;
Lavau et al., 1997; Smith et al., 2011), we then tested the role
of Cbx8 in MLL-AF9 leukemogenesis in vivo. The MigR1-MLL-
AF9 construct, which expresses both MLL-AF9 and GFP, was
used to retrovirally transduce Lin- BM cells derived from the
Cbx8f/f; Cre+ mice, in the presence or absence of 4-OHT. These
cells were then transplanted into syngeneic mice for accessing
their leukemogenic potential. Complete Cbx8 excision in the
donor cells was achieved by 4-OHT treatment, as confirmed
by genotyping the peripheral blood of the recipient mice 3 weeks
post-transplant (Figure S3M). Consistent with our in vitro find-
ings, mice receiving Cbx8-deficient, MLL-AF9-transduced
cells failed to develop leukemia, whereas mice receiving WT
MLL-AF9-transduced BM all died of leukemia, as evidenced by
marked splenomegaly and extensive infiltration of peripheral
blood, spleen, and liver (Figures 3H and 3J; Figure S3N). As
expected, flow cytometry analysis showed that BM from the
leukemic mice was replaced by GFP-positive, MLL-AF9-trans-
formed cells (>99%). In contrast, BM from the mice receiving
Cbx8-depleted donor cells was negative for GFP expression
(Figure 3I). These results strongly demonstrate that CBX8 is
required for MLL-AF9-induced leukemogenesis.
Notably, a previous study has shown that CBX8 also interacts
with anotherMLL fusion partner, ENL, which is also a component
of the EAP (or the related AEP) complex (Garcia-Cuellar et al.,
2001). Therefore, it is likely that CBX8 is not only required for.
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MLL Requires CBX8 for LeukemogenesisMLL-AF9 leukemogenesis but also involved in leukemic transfor-
mation by otherMLL fusion proteins that interact with the EAP (or
the related AEP and the DotCom) complex, such as MLL-ENL.
Indeed, similar to MLL-AF9, Cbx8 is essential for initiation and
maintenance of leukemic transformation induced by MLL-ENL,
as shown by BMT assays (Figures S3D–S3G). This finding
suggests that the dependence on CBX8 of leukemic transforma-
tion is not restricted to MLL-AF9 but may apply to other MLL
fusion proteins as well.
CBX8 Is Crucial for Proliferation and Survival
of MLL-AF9-Transformed Leukemic Cells
and for MLL-AF9-Induced Transcriptional Activation
To explore the underlying mechanisms of Cbx8-dependent
oncogenic transformation, we first investigated whether the
Cbx8 dependence is specific for certain MLL-rearranged trans-
formation or for leukemic transformation in general. Using the
conditional Cbx8 knockout mice, we assessed the impact of
Cbx8 deletion on leukemic transformation by E2A-HLF, a leuke-
mogenic fusion protein that transforms through Hox-indepen-
dent pathways (Ayton and Cleary, 2003). Despite the complete
depletion of the Cbx8 protein achieved by 4-OHT treatment,
neither the initiation nor the maintenance of E2A-HLF-induced
leukemic transformation was affected, suggesting the specificity
of Cbx8-dependent transformation (Figures S3H–S3L). Similar
results were observed with Hoxa9/Meis1-transformed cells
(data not shown). Together, these findings suggest that Cbx8
plays a specific role in leukemic transformation by certain MLL
fusion proteins, such as MLL-AF9.
We then examined whether Cbx8 is important in regulating the
proliferation of MLL-AF9 leukemic cells and found that the Cbx8
shRNA, but not the scrambled control, decreased the growth
rate of MLL-AF9 leukemic cells (Figure 4A). The phenotype
was even more dramatic in primary murine BM cells, where we
observed a complete growth arrest in liquid-cultured, MLL-
AF9-transformed BM cells (Cbx8f/f; Cre+) with Cbx8 excision
by 4-OHT treatment, whereas no such effect was observed in
control cells (Cbx8f/f; Cre) (Figures 4B and 4C). In agreement
with these observations, the apoptotic population of MLL-AF9
leukemic cells increased upon Cbx8 depletion by 4-OHT treat-
ment, but not in the control cells (Figure S4A). Additionally, we
consistently observed a slight decrease of the S phase cell pop-
ulation upon Cbx8 depletion in MLL-AF9 leukemic cells (Fig-
ure S4B). However, the effect was rather minor, suggesting
that the dramatic proliferation defect of MLL-AF9 cells upon
Cbx8 depletion is not mainly due to cell-cycle arrest.
A well-established oncogenic mechanism of MLL-AF9 trans-
formation is the constitutive activation of the HOX genes, partic-
ularly HOXA9 along with the HOX cofactor MEIS1 (Armstrong
et al., 2002; Ayton andCleary, 2003; Kumar et al., 2004), whereas
CBX8 was previously shown to be involved in transcriptional
repression (Dietrich et al., 2007; Maertens et al., 2009). The
seemingly opposite effects of CBX8 and MLL-AF9 on transcrip-
tional regulation raise an intriguing question: What role does
CBX8 play in MLL-AF9-induced transcriptional activation? To
address this question, we examined Hoxa9 expression in MLL-
AF9-transformed primary BM transduced with the Cbx8 shRNA.
Compared to the control, Cbx8 downregulation led to a marked
suppression of Hoxa9 expression (Figure 4D). A similar effectCanwas observed in MLL-AF9-transformed Cbx8f/f; Cre+ BM,
following Cbx8 excision by 4-OHT treatment, but not in the
control cells (Figure 4E; Figure S4C). To further confirm that
the impact of Cbx8 on Hoxa9 expression is dependent on the
interaction between Cbx8 and MLL-AF9, we compared the
Hoxa9 expression in primary BM cells transduced by WT MLL-
AF9 or by the mutants lacking the Cbx8 interaction (T542A and
T554A). Notably, MLL-AF9mutant-transduced cells show signif-
icantly reduced Hoxa9 expression, compared to the cells trans-
duced by WT MLL-AF9 (Figure 4F). It is noteworthy that the cells
examined in this experiment were harvested after the second
round of selection because very few mutant-transformed cells
survived the third round of selection. Therefore, few residual
nontransformed progenitors may account for the detected
Hoxa9 expression in the mutant-transformed cells, suggesting
that the reduction ofHoxa9 expression in themutant-transduced
cells could be even greater. Nevertheless, these data strongly
indicate that Cbx8 serves as a coactivator of MLL-AF9,
promoting Hoxa9 upregulation in MLL-AF9-transformed cells.
To further assess the specificity of the role of Cbx8 in Hoxa9
transcriptional regulation, we examined the effect of Cbx8
knockdown on Hoxa9 expression in several human and murine
leukemic cell lines. CBX8-inducible knockdown stable cell
lines were generated by lentiviral transduction of a TRIPZ-RFP-
shCBX8 construct in three human leukemic cell lines. The
THP-1 and Mono Mac 6 (MM6) cells are transformed by MLL-
AF9, whereas K562 is a BCR-ABL-transformed cell line that
serves as a control. As expected, knocking down of CBX8
induced by doxycycline treatment significantly decreased
HOXA9 expression in both MLL-AF9-transformed cell lines
(MM6 and THP-1), but not in the control cell line (Figure S4D).
Consistent with this observation, Cbx8 knockdown by shRNA
led to a marked decrease of Hoxa9 expression in a murine
MLL-AF9 cell line, but not in the Hoxa9-independent E2A-HLF
cell line (Figure S4E). These findings suggest that Cbx8 specifi-
cally contributes to MLL-AF9-induced Hoxa9 transcriptional
activation.
In order to mechanistically understand how Cbx8 facilitates
MLL-AF9-induced Hoxa9 upregulation, we investigated the
effect of Cbx8 on Hoxa9 promoter activity in the presence of
MLL-AF9. We first performed dual luciferase assays in 293 cells
transfected with a MLL-AF9 responsive luciferase construct,
under the control of the murine Hoxa9 promoter (Hoxa9-LUC).
Our data show that disrupting the CBX8 interaction by the point
mutation of T542A or T554A significantly decreased the activa-
tion of the Hoxa9 promoter by MLL-AF9 (T542A: p < 0.01;
T554A: p < 0.01; Figure 4G). Consistent with this result, knocking
down the CBX8 level by siRNAs reduced the MLL-AF9-induced
transcriptional activation by around 50% (p < 0.01; Figures 4H
and 4I). Notably, neither the point mutations nor CBX8 knock-
down significantly affected MLL-AF9 expression, indicating
that the reduction in Hoxa9 promoter activity was not due to a
general decrease in the MLL-AF9 level (Figures S4F and S4G).
A similar response was observed using another MLL-AF9
responsive luciferase reporter containing the thymidine kinase
promoter and multimerized Myc E box, further supporting
the importance of Cbx8 in MLL-AF9-induced transcriptional
activation (Figures S4H and S4I). We then carried out chromatin
immunoprecipitation (ChIP) in MLL-AF9-transformed murinecer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Inc. 567
Figure 3. Cbx8 Is Required for Both Initiation and Maintenance of MLL-AF9 Leukemic Transformation
(A) Schematic showing the floxed Cbx8 and the primers used for detecting the floxed and the excised Cbx8.
(B) Genotype analysis showing the efficiency of Cbx8 excision induced by 4-OHT treatment in primary BM from Cbx8f/f; Cre+ mice, with ethanol treatment
as a control (EtOH).
(C) Experimental scheme for the BMT assays with Cbx8 excision in primary BM from Cbx8f/f; Cre+ and Cbx8f/f; Cre mice. The first experimental procedure
was performed as described in Figure 2A, except that 4-OHT or ethanol was added during MLL-AF9 retroviral transduction. The second experiment was per-
formed as described in Figure S2A, except using 4-OHT treatment instead of shCbx8 transduction.
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Figure 4. CBX8 Is Crucial for Proliferation
and Survival of MLL-AF9-Transformed
Leukemic Cells and for MLL-AF9-Induced
Transcriptional Activation
(A) Growth curve of MLL-AF9 leukemic cells
transduced with shCbx8 or control (shScram).
Error bars represent ± SD from duplicate experi-
ments. Results from one of three independent
experiments are shown.
(B and C) Growth curves of MLL-AF9-transformed
primary BM from Cbx8f/f; Cre+ and Cbx8f/f; Cre
mice, with 4-OHT treatment compared to the
control. Error bars represent ± SD from a duplicate
experiment. Results from one of two independent
experiments are shown.
(D) RT-PCR analysis of the expression of Cbx8
and Hoxa9 in MLL-AF9-transformed primary
BM, with shCbx8 transduction compared to the
control (shScram).
(E) RT-qPCR analysis of the expression of Cbx8
and Hoxa9 in MLL-AF9-transformed primary BM
from Cbx8f/f; Cre+ mice, with 4-OHT treatment
compared to the control (EtOH).
(F) RT-PCR analysis of the Hoxa9 expression in
primary BM transduced by WT MLL-AF9 or MLL-
AF9 mutants, compared to the vector control.
Error bars represent ±SD.
(G) Luciferase assaywith aHoxa9 promoter-driven
reporter activated by WT or mutant MLL-AF9
(T542A and T554A) in 293 cells. Error bars
represent ± SD from three independent experi-
ments.
(H) Luciferase assay with the Hoxa9 promoter-
driven reporter activated by MLL-AF9, with
CBX8 knockdown (siCBX8) or control treatment
(siScram) in HeLa cells. Error bars represent ± SD
from three independent experiments.
(I) Western blot showing CBX8 expression
with siCBX8 treatment compared to the control
(siScram).
(J–L) Relative binding of Cbx8, RNAP II, and MLL-
AF9 together with WT AF9 to the Hoxa9 promoter
in MLL-AF9-transformed cells from Cbx8f/f; Cre+
mice, with 4-OHT treatment compared to the
control (EtOH).
See also Figure S4.
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MLL Requires CBX8 for Leukemogenesishematopoietic cells to examine changes at the Hoxa9 promoter
in response to Cbx8 depletion. In agreement with the suppres-
sion of Hoxa9 activation, a significant decrease of RNA poly-
merase II (RNAP II) binding to the Hoxa9 promoter was detected
following Cbx8 depletion by 4-OHT treatment, whereas as ex-
pected, Cbx8 binding was essentially ablated (Figures 4J and
4K). Moreover, the collective binding of MLL-AF9 fusion protein(D and E) Relative CFU of MLL-AF9-transduced cells in the two experimental se
(F) Representative INT-stained colonies in methylcellulose.
(G) Wright-Giemsa-stained cells isolated after transformation selection. Scale ba
(H) Kaplan-Meier survival analysis of mice transplanted with Cbx8D/D (n = 5) or C
(I) GFP expression of BM from the transplanted mice, assessed by flow cytomet
(J) Wright-Giemsa staining of peripheral blood (PB) smear and BM and histology
See also Figure S3.
Canand WT AF9 was not affected by Cbx8 depletion, as shown by
ChIP using an anti-AF9 antibody (Figure 4L). Because WT AF9
is also a component of the MLL-AF9 complex, and our previous
results already showed that the Cbx8 interaction is not required
for the assembly between the EAP complex and the MLL-AF9
fusion protein (Figures 1F and 1G; Figures S1C and S1D), this
observation suggests that the recruitment of the MLL-AF9ttings. Error bars represent ± SD from two independent experiments.
rs, 50 mm.
bx8f/f (n = 5) donor BM.
ry.
of liver and spleen from the transplanted mice. Scale bar, 50 mm.
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Figure 5. Ring1b Knockdown Does Not
Recapitulate the Effects of Cbx8 Knock-
down inMLL-AF9 Leukemic Transformation
(A) coIP of endogenous RING1b with Myc-CxxC-
AF9 in 293 cells. A fraction (3%) of cell lysate was
used for input control.
(B) Relative CFU of MLL-AF9 leukemic cells with
Ring1b knockdown by two individual shRing1b
molecules, compared to the control (shScram).
Error bars represent ± SD from three independent
experiments.
(C) Representative INT-stained colonies in meth-
ylcellulose.
(D) Growth curve of MLL-AF9 leukemic cells with
Ring1b knockdown, compared to the control.
Error bars represent ± SD from a duplicate
experiment. Results from one of three indepen-
dent experiments are shown.
(E) RT-PCR analysis of Hoxa9 expression in
MLL-AF9 leukemic cells with Ring1b knockdown,
compared to the control.
(F) RT-PCR analysis of Ring1b expression in
MLL-AF9 leukemic cells, confirming the knock-
down efficiency. Error bars represent ±SD.
(G and H) Experiments were performed as
described in Figures 4H and S4I, except using
siRNAs specifically targeting RING1b (siRING1b)
in place of siCBX8. Error bars represent ± SD from
three independent experiments.
(I) Western blot showing RING1b expression with
siRING1b treatment, compared to the control
(siScram).
See also Figure S5.
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MLL Requires CBX8 for Leukemogenesiscomplex to the Hoxa9 promoter is not significantly affected by
the loss of Cbx8, which is also consistent with previous reports
regarding the importance of the retained MLL portion in MLL
fusion complex localization, rather than the fusion partner
portion (Ayton et al., 2004; Milne et al., 2010; Muntean et al.,
2010; Slany et al., 1998; Yokoyama and Cleary, 2008). Similar
findings were observed using CBX8-inducible knockdown
MLL-AF9-transformed cell lines (Figures S4J–S4M), further
supporting that Cbx8 regulates MLL-AF9 target promoter
activity, thereby contributing to MLL-AF9-induced transcrip-
tional activation, without affecting the collective localization of
MLL-AF9 and WT AF9.
Role of CBX8 in MLL-AF9 Leukemic Transformation and
Transcriptional Activation Is Independent of PRC1
To date, the only reported functional characterization of Cbx8 is
its role as a transcriptional repressor in PRC1, whereas our data
indicate that Cbx8 serves as a transcriptional coactivator in the
presence ofMLL-AF9. These opposing transcriptional regulatory
roles suggest that Cbx8 functions in a PRC1-independent
manner in MLL-AF9 leukemic transformation. It has been shown
that Ring1b, another PRC1 component, is required for the
stability of PRC1 complexes (Leeb and Wutz, 2007; van der
Stoop et al., 2008). In addition, previous studies have indicated
that Ring1b also interacts with AF9 (Monroe et al., 2011), which570 Cancer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Incwe confirmed by IP experiments showing that endogenous
RING1b consistently coprecipitates with the MLL-AF9 fragment,
CxxC-AF9 (Figure 5A). Therefore, to test our hypothesis of the
potential PRC1-independent function of Cbx8, we first assessed
the impact of Ring1b on MLL-AF9 leukemic transformation by
BMT assays. Two individual shRNA molecules specifically tar-
geting Ring1b were used to effectively knock down Ring1b
expression in MLL-AF9-transformed leukemic cells. Reduction
in Ring1b expression in these experiments did not impair the
transformation ability of MLL-AF9 (Figures 5B, 5C, and 5F).
Knocking down Ring1b did not significantly affect the growth
rate or Hoxa9 expression in MLL-AF9 cells either (Figures 5D
and 5E). We also performed dual luciferase assays to examine
the impact of knocking down RING1b by siRNA on the MLL-
AF9 target promoter activity. Despite the marked reduction of
RING1b expression shown by western blot analysis, MLL-AF9-
induced transactivation of the target promoters was not sup-
pressed by RING1b knockdown (Figures 5G–5I). Similar to our
observations with Ring1b, knockdown of Bmi1, another core
PRC1 component, did not affect the transformation ability,
growth rate, or transcriptional activation in MLL-AF9 leukemic
cells (Figures S5B–S5I). Consistent with these observations,
Cbx8 depletion in MLL-AF9-transformed BM cells did not affect
the global levels of Ring1b and Bmi1, as shown by western blot
analysis (Figure S5A). Taken together, these findings suggest.
Figure 6. CBX8 Regulates the Localization
of TIP60, Whose Downregulation Pheno-
copies the Effects of Cbx8 Knockdown in
MLL-AF9 Leukemic Transformation
(A) coIP of endogenous TIP60 with FLAG-CBX8
in 293 cells, after Benzonase treatment. A fraction
(3%) of cell lysate was used for input control.
(B) Relative CFU of MLL-AF9 leukemic cells with
Tip60 knockdown by shRNA, compared to the
control (shScram). Error bars represent ± SD from
three independent experiments.
(C) Representative INT-stained colonies in meth-
ylcellulose.
(D) Growth curve of MLL-AF9 leukemic cells with
Tip60 knockdown, compared to the control. Error
bars represent ± SD from a duplicate experiment.
Results from one of three independent experi-
ments are shown.
(E) RT-PCR analysis of Hoxa9 expression in
MLL-AF9 leukemic cells with Tip60 knockdown,
compared to the control.
(F) RT-PCR analysis of Tip60 expression in
MLL-AF9 leukemic cells, showing the knockdown
efficiency. Error bars represent ±SD.
(G and H) Experiments were performed as
described in Figures 4H and S4I, except using
siRNAs specifically targeting TIP60 (siTIP60)
instead of siCBX8. Error bars represent ± SD from
three independent experiments.
(I) Relative binding of Tip60 to the Hoxa9 promoter
in MLL-AF9-transformed cells from Cbx8f/f; Cre+
mice, with Cbx8 excision induced by 4-OHT
treatment compared to the control (EtOH). Error
bars represent ±SD.
See also Figure S6.
Cancer Cell
MLL Requires CBX8 for Leukemogenesisthat Cbx8 functions as an MLL-AF9 cofactor to promote leuke-
mogenesis in a PRC1-independent manner.
Notably, given the finding that CBX8 is involved in the INK4a/
ARF transcriptional repression by PRC1 in fibroblasts (Dietrich
et al., 2007), it is important to determine whether the observed
effect of CBX8 on MLL-AF9 transcriptional activation is related
to its role in INK4a/ARF regulation. Therefore, we examined
the impact of Cbx8 on Ink4a/Arf expression by RT-PCR in
MLL-AF9 leukemic cells. Neither downregulation nor depletion
of Cbx8 led to Ink4a/Arf activation (Figures S8A and S8B),
confirming that the Cbx8-dependent MLL-AF9 transformation
is not due to Ink4a/Arf repression.
CBX8 Regulation of TIP60 Localization Contributes
to MLL-AF9 Leukemic Transformation
The characterization of the PRC1 independence of Cbx8 func-
tions in MLL-AF9 leukemic transformation prompted us to
explore the possible involvement of other Cbx8-interacting
proteins that may explain the role of Cbx8 in transcriptional acti-
vation. A previous study has reported that CBX8 directly inter-
acts with the histone acetyltransferase HIV Tat-interacting
protein of 60 kDa (TIP60) by high-throughput yeast two-hybrid
screens and mass spectroscopy analysis (Stelzl et al., 2005).
However, this observation has not yet been verified in any
mammalian cell system; therefore, the functional implication ofCanthis interaction remains an open question. To first confirm this
interaction, we transiently expressed FLAG-tagged CBX8 in
293 cells. Specific interaction between CBX8 and TIP60 was de-
tected by IP experiments: using an anti-FLAG antibody to pull
downCBX8, we observed that CBX8 consistently coprecipitated
with endogenous TIP60 in the presence of Benzonase, indicating
that CBX8 interacts with TIP60 in a DNA-independent manner
(Figure 6A; Figure S6A). This finding implied an intriguing possi-
bility that CBX8 promotes MLL-AF9 leukemic transformation, at
least partially through its interaction with the transcriptional
coactivator TIP60. To test this hypothesis, we first assessed
the impact of Tip60 on MLL-AF9 leukemic transformation by
BMT assays. Using shRNA molecules specifically targeting
Tip60, we observed a reduction in the colony formation ability
of MLL-AF9 leukemic cells (Figures 6B, 6C, and 6F). Moreover,
Tip60 downregulation by shRNA led to a decrease in the growth
rate and Hoxa9 expression of MLL-AF9-transformed cells (Fig-
ures 6D and 6E). Similar results were obtained using a different
shRNA pool, further supporting that Tip60 positively contributes
to MLL-AF9 leukemic transformation (Figures S6B–S6F).
To further characterize the role of Tip60 in MLL-AF9-induced
transcriptional activation, we performed dual luciferase assays
to examine the impact of TIP60 downregulation by siRNA on
the MLL-AF9 target promoter activity. A significant reduction of
TIP60 expression was confirmed by western blot analysiscer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Inc. 571
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MLL Requires CBX8 for Leukemogenesis(Figure S6G). As expected, theMLL-AF9-induced transcriptional
activation of the target promoters was significantly suppressed
by TIP60 knockdown (Figures 6G and 6H). Collectively, these
data demonstrate that knocking down Tip60 phenocopies the
effect of Cbx8 knockdown in MLL-AF9 leukemic cells, suggest-
ing a functional significance of the CBX8/TIP60 interaction in
MLL-AF9 leukemic transformation. To confirm that the observed
role of Tip60 is indeed associated with the Cbx8/Tip60 interac-
tion, we performed ChIP assays in MLL-AF9-transformed
leukemic cells, following Cbx8 depletion by 4-OHT treatment.
As expected, Cbx8 depletion resulted in decreased Tip60
binding at the Hoxa9 promoter (Figure 6I). Similar findings were
seen using MLL-AF9-transformed cell lines, MM6 and THP-1,
engineered for inducible knockdown of CBX8. In these cells,
TIP60 binding at the HOXA9 promoter was reduced upon
CBX8 downregulation induced by doxycycline treatment (Fig-
ure S6; data not shown). Together, our results suggest that
CBX8 regulates the localization of TIP60, which plays a positive
role in MLL-AF9 leukemic transformation. Of note, Tip60 down-
regulation in MLL-AF9 leukemic cells did not lead to Ink4a/Arf
activation (Figures S8C and S8D), consistent with previous
observations from Cbx8 knockdown, further supporting that
Ink4a/Arf repression does not account for the role of Cbx8 in
MLL-AF9 leukemogenesis.
Cbx8 Is Not Required for Normal Hematopoiesis
The profound impact of Cbx8 on MLL-AF9 leukemogenesis
prompted us to examine the role of Cbx8 in normal hematopoi-
esis. We first examined the effect of Cbx8 depletion on hemato-
poietic steady-state conditions in vivo. Constitutive depletion
of Cbx8 showed no aberrant phenotype, and deletion of Cbx8
by 4-OHT treatment in adult animals had no detectable effect
on any measured peripheral blood population as assessed by
complete blood count (CBC) analysis (Figures 7A–7D; Fig-
ure S7A). Moreover, both the cellularity of major hematopoietic
organs (BM, spleen, and thymus) and the cell numbers of mature
hematopoietic populations as defined by flow cytometry were
similar between Cbx8-deficient mice and controls (Figures 7E–
7H; Figures S7C–S7E). To address potential effects of Cbx8
deletion on primitive long-term hematopoietic stem cells (LT-
HSCs), we combined flow cytometry for characterization of
progenitor populations and competitive BM transplantation
assays. These analyses revealed no detectable differences in
LT-HSC numbers (Figure 7I) or hematopoietic reconstitution
ability of Cbx8WT or deficient BM in lethally irradiated recipients
(Figure 7K). In addition, the total progenitor output from the BM
of Cbx8-deficient animals was similar to controls, as measured
by colony-forming assays (Figure 7J; Figure S7B). Together,
these findings indicate that Cbx8 is not required for steady-state
hematopoiesis, LT-HSC maintenance, or stem and progenitor
cell function.
DISCUSSION
Our study establishes CBX8 as an essential cofactor required
for MLL-AF9-induced transcriptional activation and leukemic
transformation (Figure 8). CBX8 is one of the five human homo-
logs of the Drosophila Pc protein. Although all CBX proteins
share highly conserved chromodomains and Pc boxes, their572 Cancer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Incdifferent sizes and the presence of other motifs suggest poten-
tially different functions (Whitcomb et al., 2007). Indeed, previous
studies have reported that mice deficient for different PRC1
components show only a partial overlap in phenotype, raising
the possibility of PRC1-independent functions of these compo-
nents that may be context dependent and involve other protein
complexes (de Napoles et al., 2004; Katoh-Fukui et al., 1998;
Leeb and Wutz, 2007; Suzuki et al., 2002; Voncken et al.,
2003). The present study has uncovered such a PRC1-indepen-
dent function of CBX8 in MLL-AF9-induced transcriptional
regulation. Interestingly, contrary to its role as a transcriptional
repressor in PRC1, CBX8 serves as a transcriptional coactivator
in the MLL-AF9 complex. Furthermore, CBX8 is present in
the EAP (or the related AEP and the DotCom) transcriptional
activation complex (Mohan et al., 2010a; Monroe et al., 2011;
Yokoyama et al., 2010) and is also required for the leukemic
transformation induced by MLL-ENL, another EAP-interacting
MLL fusion protein, implying a broader role of CBX8 in MLL-
rearranged leukemogenesis, which warrants further exploration.
Importantly, consistent with our observations, a recent study
showed that Bmi1 is not required for MLL-AF9-induced leuke-
mogenesis (Smith et al., 2011). Moreover, our findings that
neither Cbx8 downregulation or depletion nor Tip60 knockdown
induced Ink4a/Arf expression further support that the role of
CBX8 in MLL-AF9 leukemogenesis is independent of PRC1.
In addition to the MLL fusion partners, CBX8 has previously
been shown to directly interact with the HAT TIP60 (Stelzl
et al., 2005). Tip60 is a member of the MYST (Moz, Ybf2/Sas3,
Sas2, Tip60) protein family, the largest family of HATs that is
present in all eukaryotes (Voss and Thomas, 2009). Histone
acetylation near promoters is associated with transcriptional
activation; therefore, HATs generally promote transcriptional
activation (Mills, 2010). Several TrxG complexes are known to
recruit HATs during normal development. For example, the
HAT MYST1 has been purified in WT MLL complex, and the
HAT CREB-binding protein (CBP) is known to interact with
both MLL and another TrxG protein ASH1 (Bantignies et al.,
2000; Dou et al., 2005; Ernst et al., 2001; Petruk et al., 2001).
Under normal physiological conditions, HATs function as a coac-
tivator to facilitate TrxG-induced transcriptional activation,
antagonizing the transcriptional repressive effect of the PcG
complex (Mills, 2010; Pasini et al., 2010). This mechanism
contributes to the active HOXA9 expression in hematopoietic
stem cells and early progenitors (Figure 8). Moreover, MLL is
fused to CBP or P300 in a subset of acute leukemias (Wang
et al., 2005). However, previous studies have not reported
HATs as a component of the EAP complex, which is recruited
by the most common MLL fusion partners. Therefore, whether
HATs contribute to transcriptional activation induced by
common MLL-rearranged oncoproteins remains unknown. Our
finding of the CBX8-dependent TIP60 localization at the
HOXA9 promoter indicates that this transcriptional activation
mechanism is likely to be adopted byMLL fusion proteins to acti-
vate target gene expression, such as HOXA9. Interestingly,
a previous RNAi screening study in mouse embryonic stem cells
(ESCs) showed that Tip60 is required for pluripotency, whereas
MLL myeloid leukemia stem cells have been shown to share
the transcriptional program with ESCs, rather than adult stem
cells (Fazzio et al., 2008; Somervaille et al., 2009). Together,.
Figure 7. Cbx8-Depleted Mice Show Normal Hematopoiesis
(A–D) Peripheral blood CBC analysis of (A) platelets, (B) white blood cells, (C) red blood cells, and (D) hemoglobin content of Cbx8 floxed (f/f) and deleted (D/D)
mice. The experiment was performed 4 weeks after complete Cbx8 excision in vivo.
(E–H) Absolute quantification of total BM cellularity (E), erythroid cells (Ter119+; F), developing B lymphocytes (AA4.1+CD19+B220+; G), and myeloid cells
(CD11b+Gr1+; H) from Cbx8f/f and Cbx8D/D, analyzed by flow cytometry (error bars represent mean + SD; n = 5 mice/genotype).
(I) Flow cytometric analysis of LT-HSCs (CD150+CD48-LSK) from Cbx8f/f and Cbx8D/D mice (error bars represent mean + SD; n = 5 mice/genotype).
(J) Colony-forming assays using BM from Cbx8f/f and Cbx8D/D mice. The data included four independent experiments per genotype (error bars represent
mean + SD; n = 3 plate/experiment).
(K) Competitive BM transplantation at competitor: tester ratios of 1:1 (n = 10/group), 1:3 (n = 5 mice per group), and 1:9 (n = 5 mice per group). No difference
between Cbx8f/f and Cbx8D/D mice was observed in tester contribution to myeloid reconstitution at any ratio (data represent mean ± SD).
(E)–(K) were performed 5–7 months after complete Cbx8 excision in vivo.
See also Figure S7.
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MLL Requires CBX8 for Leukemogenesisthese observations suggest a possible functional association
between the TIP60-regulated signaling network and the tran-
scriptional program in MLL-rearranged leukemic cells, raisingCanthe possibility that TIP60 may be involved in establishing the
transcriptional program required for MLL-AF9-induced leuke-
mogenesis (Figure 8). Given the broad involvement of TIP60 incer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier Inc. 573
Figure 8. Schematic Model Illustrating Role of CBX8 in Promoting
MLL-AF9-Induced Leukemogenesis
Top view shows that recruitment of WT MLL is required for transcriptional
regulation ofHox gene expression in HSCs and early progenitor cells. Left view
illustrates that during normal hematopoiesis, Hox gene expression decreases
due to the transcriptional repression of PcG proteins. Right view shows that In
MLL-AF9 leukemic cells, CBX8 interacts with MLL-AF9 at the target gene loci
to facilitate transcriptional activation, possibly by recruiting transcriptional
cofactors such as TIP60, thereby promoting leukemogenesis. See also Fig-
ure S8.
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MLL Requires CBX8 for Leukemogenesismultiple biological processes (Sapountzi et al., 2006), it is unclear
whether the role of TIP60 in MLL-AF9 leukemogenesis is as
specific as that of CBX8. This mechanismwarrants further inves-
tigation. Finally, our identification of the critical role of the CBX8/
MLL-AF9 interaction in leukemogenesis but not viability or
normal hematopoiesis suggests that developing small molecule
inhibitors targeting CBX8 represents a promising therapeutic
strategy for MLL-rearranged leukemias.
EXPERIMENTAL PROCEDURES
Cell Culture and Animal Use
HeLa and 293 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and nonessential
amino acids.MLL-AF9,MLL-ENL, and E2A-HLF cells were cultured in Iscove’s
modified Dulbecco’s medium (IMDM) supplemented with 15% fetal calf serum
(FCS; STEMCELL Technologies). THP-1, MM6, and K562 cells were cultured
in RPMI-1640 medium supplemented with 10% FBS. The Tripz-RFP-shCBX8
expression was induced by 0.5 mg/ml doxycycline. Full details of conditional
gene targeting of Cbx8 and analysis of Cbx8/ embryos will be provided in
a subsequent manuscript (H.K., unpublished data). All animal experiments in
this study were approved by the University of Michigan Committee on Use
and Care of Animals and Unit for Laboratory Animal Medicine (ULAM).
In Vivo Leukemogenesis Assays
Lin- BM was isolated from 6- to 8-week-old mice (Cbx8f/f; Cre+) injected with
5-fluorouacil (see Supplemental Experimental Procedures). The harvested
Lin- BM cells were retrovirally transduced withMigR1-MLL-AF9 by two rounds
of spinoculation in the presence of either 4-OHT (100 nM) or ethanol as a
control. The cells were then counted and injected intravenously through the
tail vein to cohorts of lethally irradiated (900 rads) C57BL/6 mice (3.5 3 104
cells per injection). Recipient mice were maintained on antibiotics for 2 weeks
after transplantation.
CBC Analysis
For in vivo Cbx8 excision, Cbx8f/f; Cre+ mice were treated with corn oil or
50 mg/kg 4-OHT by i.p. injection for 5 continuous days. Four weeks after injec-
tion, peripheral blood was used harvested in EDTA (ethylenediaminetetraace-
tic acid)-containing Microtainer tubes (BD Biosciences) and subjected for
analysis performed by the ULAM laboratory. Meanwhile, genotyping was
performed using genomic DNA extracted from peripheral blood.574 Cancer Cell 20, 563–575, November 15, 2011 ª2011 Elsevier IncFlow Cytometry and Cell Sorting
After blocking nonspecific binding with unlabeled rat plus mouse IgG (Sigma-
Aldrich), cells were stained on ice in PBS plus 4% FCS and sorted on
FACSAria (BD Biosciences). Analysis was performed on LSR II, FACSCanto,
or FACSAria (BD Biosciences). Files were analyzed in FlowJo (TreeStar).
Statistical Analysis
Statistical significance was determined by Student’s t test using the Excel
software (Microsoft 2007); p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.09.008.
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